Nucleotides are key subunits for nucleic acids and provide energy for intracellular metabolism. 2 They can also be released from cells to act physiologically as extracellular messengers or 3 pathologically as danger signals. Extracellular nucleotides stimulate membrane receptors in the 4 P2 and P1 family. P2X are ATP-activated cation channels; P2Y and P1 are G-protein coupled 5 receptors activated by ATP, ADP, UTP and UDP or adenosine, respectively. Renal P2 receptors 6 influence both vascular contractility and tubular function. Renal cells also express 7 ectonucleotidases that rapidly hydrolyze extracellular nucleotides. These enzymes integrate this 8 multi-receptor purinergic-signaling complex by determining the nucleotide milieu, as well as 9 titrating receptor activation.
Introduction 22
Since their discovery in the 1970s, P2 purinergic receptors (P2R) have evolved from an initially 23 contentious biological concept 1 , through to a progressive understanding of their complex 24 physiological actions, emerging now as attractive and 'druggable' targets for disease 2, 3 . To date, 25 the most advanced potential therapeutic P2R targets are antagonists for P2Y12R to inhibit 26 thrombosis 4 , and P2X7R for the treatment of chronic inflammatory diseases such as 27 rheumatoid arthritis 5 and COPD 6 . Several P2X7R antagonists have completed Phase 2 clinical 28 trials, but despite pre-clinical promise, these compounds have failed to deliver the expected 29 benefit and so interest in P2X7R has declined. In this concise review we cover purinergic 30 signaling in the kidney and explore the contribution of this system to renal physiology and 31 disease. The main focus is on the role of P2X receptors , particularly P2X7R, in renal injury and 32 disease. P2X7R can orchestrate interactions between the immune and vascular systems, and 33 defining this complex interaction as inflammation and injury develop may help us unlock the 34 potential of P2X7R antagonists as renal therapeutics. 35
36

P2 receptors and purinergic signaling in the kidney 37
Purinergic receptors are sub-classified as P1R that bind adenosine and P2R that are activated by 38 purine/pyrimidine nucleotides; P2R are in turn subdivided into P2YR and P2XR. The 8 P2YRs are 39 coupled to G-proteins and are activated with differing selectivity by adenosine triphosphate 40 (ATP), adenosine diphosphate (ADP), uridine triphosphate (UTP) and uridine diphosphate (UDP). 41
The 7 P2XRs are trimeric ligand-gated ion channels activated by ATP, but not, or only weakly, by 42 ADP or adenosine monophosphate (AMP). The molecular properties of these receptors and 43 their ligands are described in detail in the IUPHAR/BPS Guide to Pharmacology: 44 http://www.guidetopharmacology.org. 45
P2 receptors control renal vascular and microvascular function 70
P2 receptors are expressed throughout the vasculature and microvasculature (Figure 2) and 71 strongly influence vessel function 16 . The renal vasculature and microvasculature also expresses 72 NTPDase1 (CD39) that hydrolyses ATP to ADP and AMP, and thereby rapidly curtail purinergic 73 signaling 17 . P2X1R is the dominant receptor in vascular smooth muscle and application of ATP 74 to the adventitia evokes contraction in the pre-glomerular vasculature 18, 19 . P2X1R null mice 75 display an attenuated pressure-induced constriction of the afferent arteriole 20 and targeted 76 deletion of NTPDase1 prolongs the half-life of extracellular ATP, enhancing the vascular 77 response to increased pressure 21 . 78
Direct renal artery infusion of ATP increases blood flow, causing vasodilation due to production 79 of nitric oxide (NO) by the endothelium 22 and also NO-independent vasodilatation induced by 80 intra-renal prostanoids 23 . The P2 receptor subtype(s) that mediates the vasodilatatory response 81 to ATP is unknown. In human arterial endothelial cells and endothelial cells cultured from the 82 mouse pulmonary artery, P2X4R is the most abundantly expressed receptor, followed by P2X7R 83 [24] [25] [26] . P2X4R mediates the release of NO in response to increased shear stress 24 . This response is 84 lost in P2X4R null mice, which have endothelial dysfunction and hypertension 25 . P2X7R 85 activation seems to promote a tonic vasoconstriction of both the pre-glomerular arteries and 86 medullary microcirculation 14 , which is discussed more below. Other P2 receptors can influence 87 endothelial function, for example, vasodilatation caused by UDP is abolished in P2Y6R null mice 88 27 . The descending vasa recta are also affected by extracellular nucleotides, since infusion of 89 ATP into the renal artery reduces medullary blood flow as a result of P2X1R activation 23 , and 90 ATP released from sympathetic nerves causes constriction of vasa recta pericytes 28 . 91
92
Multiple P2R subtypes are expressed in glomerular cells (Figure 2) P2R exert a largely inhibitory effect on tubular electrolyte transport and this, together with 109 expression in specific nephron segments, has been reviewed extensively elsewhere 35 and is 110 summarized in Figure 2 . The processes are best defined for sodium flux, which is tonically 111 suppressed by P2R activation in several nephron segments 36 . It is likely that such paracrine 112 control by extracellular nucleotides provides a route for rapid modulation of tubular transport 113 that can link solute and fluid delivery to adaptive transport capacity, for example adenosine-114 mediated tubuloglomerular feedback is impaired in CD73 -/-mice 37 . This form of control can 115 integrate with more slowly adapting hormonal systems, for example the renin-angiotensin-116 aldosterone system (RAAS) to regulate the phenomenon of aldosterone escape 38 . Indeed, ATP 117 release by tubular cells, stimulated by increased flow, contributes to the control of extracellular 118 fluid volume by the kidney, and blood pressure regulation, as discussed below. 119
120
Proximal tubule 121
The proximal tubule, which expresses apical P2Y1R and P2X5R, and basolateral P2Y4R and 122 P2Y6R 39, 40 , accounts for reabsorption of ~65% of the filtered sodium load. Extracellular 123 nucleotides inhibit the major sodium transporters in this segment, NHE3 41 , NaPi2 42 and Na,K-124 underpins the flow-dependent increase in NO production 49 and subsequent inhibition of apical 140 NKCC2 and basolateral Na,K-ATPase activity 50 . Studies in knockout mice suggest P2X4R and 141 P2Y2R contribute to this signaling arc 51, 52 . 142 Extracellular ATP has long been known to inhibit the epithelial sodium channel (ENaC), the rate -143 limiting step for sodium transport in the connecting tubule and collecting duct 53 . Studies in 144 isolated segments show that ATP activates P2Y2R to reduce the open probability of ENaC [54] [55] [56] . 145
P2yr2 null mice lack the tonic suppression of ENaC and are hypertensive 54 
. Studies in vivo 146
suggest that P2X4R activation also inhibits ENaC 53, 57 and our own pilot studies in a P2X4R null 147 mouse suggest that this receptor may be important in the modulation of sodium transport by 148 aldosterone (Craigie et al, unpublished) . 149
150
P2R and blood pressure regulation 151
Hypertension is a major modifiable risk factor for cardiovascular and renal disease and is highly 152 prevalent 58 . Human genetic studies have found an association between SNPs in P2XR encoding 153 genes and blood pressure or cardiovascular disease. The loss of function variant rs28360472 in 154 P2RX4 associates with increased pulse pressure 59 , itself an important cardiovascular risk factor. 155
An intronic SNP (rs591874) in the gene encoding P2X7R is associated with elevated blood 156 pressure 60 . The loss of function variant rs3751143 is common (25% heterozygosity and up to 3% 157 homozygosity) and protects against ischemic stroke 61 . The physiology of P2RX7 genetic 158 variation is almost certainly subtle, if not complex. For example, rs3751143 does not associate 159 with impaired endothelial dysfunction or vascular stiffness in essential hypertensives 62 , but 160 does confer a significantly reduced sensitivity to P2X7R antagonism 63 . 161
Pressure-natriuresis is an important mechanism of long-term blood pressure control 64 and is 162 modulated by paracrine factors that inhibit sodium transport in the renal proximal tubule, 163 including extracellular nucleotides. Microdialysis experiments reveal a direct relationship 164 between renal artery perfusion pressure and the concentration of ATP in the interstitial fluid of 165 the kidney cortex 65 . As mentioned earlier, extracellular nucleotides inhibit the key transporters 166 in the proximal tubule [41] [42] [43] . This natriuretic effect is buttressed by inhibition of sodium transport 167 in the distal nephron. Increased flow through the collecting duct promotes ATP secretion to 168 inhibit ENaC. This ATP release is abolished in connexin 30 knockout mice, severely attenuating 169 the pressure-natriuresis response 9 . Consistent with this, mice over-expressing human 170 NTPDase1 (CD39), a cell surface enzyme that scavenges extracellular nucleotides, display a small 171 impairment of the natriuretic response to a high sodium diet and concomitant aldosterone 172 infusion 66 . It is assumed that P2Y2R mediates the inhibitory effect of ATP on distal tubule 173 sodium transport. Receptor agonists have been considered as potential antihypertensives. 174
P2yr2 null mice display enhanced ENaC activity and are hypertensive. Surprisingly, blood 175 pressure is salt resistant 67 and endothelial dysfunction with impaired NO release may be causal. 176
Recent studies also suggest that ATP can inhibit ENaC indirectly: in IMCD cells, activation of 177 P2X7R promotes synthesis of endothelin-1, which is pro-natriuretic due to ETB-mediated 178 inhibition of ENaC 68 . However, the significance of this cell line-based study is not clear, since 179 acute P2X7R antagonism in vivo improves the pressure-natriuresis relationship 14 . 
P2XR and renal injury 200
There is consistent pre-clinical evidence supporting a role for P2X7R in inflammation (Figure 3 In the normal kidney P2X7R is typically only present at low levels, often undetectable by RNA 209 analysis in whole kidney extracts. The receptor is normally localized to certain compartments, 210 particularly the vasculature and microvasculature, at least in the rat 7, 14, 72 . A wealth of data 211
shows that injury/inflammation increases expression in renal cells. For example, TNFα can 212 induce expression of P2X7R in cultured mesangial cells 74 . In renal biopsy material from patients 213 with lupus nephritis, increased expression of P2X7R protein has been found 75 . Nevertheless, it 214 remains to be investigated whether the extent of P2X7R expression correlates with the severity 215 of clinical disease and a more detailed study with larger patient numbers is needed. There is also recent evidence in lupus prone mice that treatment with a P2X7R antagonist can 249 decrease the severity of renal injury and levels of dsDNA antibodies 78 . 250
251
Acute kidney injury 252
Renal ischemia-reperfusion injury (IRI) is a common occurrence in many clinical settings from 253 sepsis to major surgery, including renal transplantation. There is increased expression of P2X7R, 254 mainly in the renal tubules, in a mouse model of renal IRI; treatment with A438079 reduced 255 renal expression of chemokines (MCP-1 and RANTES), p-ERK, NGAL, renal tubular injury and cell 256 death 79 . 257
As well as the mentioned increase in P2X7R in a rat model of type 1 diabetes 33 , in a mouse 258 model of high fat diet-induced metabolic disease, proteinuria and albuminuria developed in the 259 wild-type mice, but not in P2X7a variant knockout mice 80 . In the high fat diet fed mice there 260 was also increased renal expression of P2X7R and components of the NLRP3 inflammasome that 261 were attenuated in the high fat diet fed P2X7R knockout mice, as was renal expression of 262 chemokine CCL2, macrophage infiltration and expression of extracellular matrix protein. Moreover, increased expression of P2X7R and inflammasome components were found in renal 264 tissue from patients with glomerulonephritis 75 . 265
266
Fibrosis 267
Purinergic signaling is involved in tissue remodeling (Figure 3) and several studies in various 268 tissues suggest that these pathways may also drive tiss ue fibrosis in chronic injury, one feature 269 of which is a sustained increase in ambient concentrations of ATP, ADP, UTP and UDP 81 . Tissue 270 fibroblasts express multiple P2R subtypes and respond to extracellular nucleotides by activating 271 key pathways for the production of extracellular matrix. In cardiac fibroblasts, for example, 272 P2Y2R activation is strongly pro-fibrotic 82 , and activation of P2X4R and P2X7R promotes 273 ERK1/2-dependent fibroblast proliferation 83 . This cluster of P2Rs is also relevant to the kidney 274 in which fibroblasts and mesangial cells mainly determine ECM deposition. In this context, 275 P2Y2R activation increases mesangial cell proliferation 74 and P2X7R activation increases matrix 276 production by mesangial cells 84 . 277
The role of P2 receptors in renal fibrosis has been investigated in the unilateral ureteral 278 P2X4R is closely related to P2X7R and there has been ongoing controversy over whether P2X4R 290 and P2X7R can form heterotrimers 87, 88 . The potential importance of P2X4R in renal fibrosis has 291 been investigated in the UUO model. Surprisingly, the P2X4R knockout mice showed increased 292 renal fibrosis following induction of UUO associated with increased expression of TGFβ1 and 293 connective tissue growth factor (CTGF, also known as CCN2), and increased amounts of type I 294 collagen 89 . These results suggest that P2X7R is pro-fibrotic in this model and that P2X4R may 295
have an anti-fibrotic role through its regulation of pro-fibrotic growth factors. 296
More recent studies show that nucleotidases may also contribute to fibrosis by regulating the 297 half-life of ATP. ENTPD1 (CD39)-null mice are more sensitive to ischemic tissue injury than wild-298 type mice 90 , because ATP persists and its hydrolysis to protective adenosine is blunted. 299
Similarly, these null mice have more pronounced renal injury in the IRI model 91, 92 ; although in 300 this setting the role of adenosine is less certain, since the deletion of CD73, the enzyme that 301 converts AMP to adenosine, was also protective 93 . Overall, these data suggest that enzymes 302 involved in terminating P2R signaling may be less tractable as therapeutic targets than the 303 receptors themselves. Recent studies indicate that CD39 expression by T-reg lymphocytes is 304 essential for their pro-reparative role in response to chronic renal injury 94 Human P2X7R has at least 10 splice isoforms, the functions of which have not been unraveled; 315 however, in rodents, the common 'k variant' of P2X7R is much more sensitive to ATP than the 316 original full-length 'a variant' 99 . Pre-clinical data suggest that genetic variation in P2X7R will 317 increase the population wide variance of both agonist and antagonist binding affinities, 318
suggesting that we need to re-evaluate or redefine clinical trials on the basis of the P2X7R 319 "fingerprint". The tissue distribution, regulation and function of these splice isoforms in the 320 healthy kidney is just beginning to be explored; the pharmacogenomics of P2X7R and the impact 321 of disease is largely unknown. The next phase of research will define these key biological 322 processes involving P2X7R, which may not all be 'bad' 100 , and provide a better understanding of 323 how isoform-specific receptor antagonists should be deployed in kidney disease. Is this P2X7R 324 
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